Verily Health Inc. has announced new investment support from NVIDIA as it extends the fundraising effort it began in March. CU Healthcare Innovation Fund II, LP, an existing investor, is also making an additional commitment. The backing is intended to advance Verily's precision health artificial intelligence strategy and strengthen its position in the healthcare technology market.
Investment Support and Strategic Momentum
Stephen Gillett, Chairman and CEO of Verily, said the company is pleased to welcome NVIDIA as a new investor. He noted that these investments strengthen the company's ability to pursue the opportunity ahead and accelerate its vision of building a trusted foundation for healthcare. Gillett added that continued support from current investors helps bring together information and intelligence to power better decisions and unlock the potential of AI across the healthcare ecosystem.
Existing Investor Base
Verily's current investor group includes Alphabet, Series X Capital, UCHealth, and other leading organizations. The additional investment from CU Healthcare Innovation Fund II, LP builds on this established support and reinforces the company's long-term strategy. The expanded backing reflects growing confidence in Verily's approach to integrating data, technology, and artificial intelligence across the healthcare ecosystem.
Scaling the Verily Pre Platform
The new backing arrives as Verily scales adoption of its flagship data and AI platform, Verily Pre. The platform helps healthcare organizations make their data AI-ready and deploy AI responsibly across research and care. It is designed to support the growing demand for trustworthy data infrastructure in precision health.
Expanding Patient Engagement
The funding also supports the continued growth of Verily Me, the company's patient engagement offering that connects individuals with personalized health tools. Verily Me extends the company's capabilities to support people throughout their healthcare journey, from prevention to treatment and follow-up care. This expansion aligns with Verily's broader goal of making healthcare more personalized, predictive, and accessible for diverse populations.
NVIDIA Collaboration and AI Infrastructure
Verily and NVIDIA previously announced a collaboration in October 2025. Researchers using the Verily Pre Platform will be able to leverage NVIDIA AI libraries and frameworks, including NeMo, Parabricks, RAPIDS, and NVIDIA B200 GPUs. This technical foundation is intended to support more efficient and scalable AI workloads in healthcare research.
Forecast 1.0 Foundation Model
Verily developed Forecast 1.0, a foundation model that integrates genomics and electronic health record data. The model was built in collaboration with NVIDIA and is designed to improve the accuracy of predicting long-term health risks. Leveraging the NVIDIA AI stack, Forecast 1.0 achieved improved predictive performance and computational efficiency for healthcare applications.
About Verily Health
Verily is a data platform and technology company purpose-built to power AI-enabled precision health solutions that accelerate research and improve care. It operates at the intersection of technology, data science, and healthcare to transform multimodal health data into insights, models, and actions. The company aims to make healthcare more personalized, predictive, and precise for individuals and communities.
The new investment from NVIDIA and CU Healthcare Innovation Fund II highlights confidence in Verily's strategy to combine data infrastructure with advanced AI capabilities. With enhanced resources, the company expects to broaden adoption of its platform and patient engagement solutions. This development signals continued momentum for precision health technology and underscores the growing role of AI in modern healthcare.